Evidence map›Paper›PMID 29368425›Full record

ArticleMolecular genetics & genomic medicine2018

Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program.

Andrea Eisen, Kristina M Blackmore, Wendy S Meschino, Derek Muradali, June C Carroll, Vicky Majpruz, Ellen Warner, Linda Rabeneck, Anna M Chiarelli

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Clinical cancer genomic profiling.Nature reviews. Genetics · 2021
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Andrea EisenMedical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Kristina M BlackmorePrevention and Cancer Control, Cancer Care Ontario, Toronto, ON, Canada.
Wendy S MeschinoGenetics, North York General Hospital, Toronto, ON, Canada.
Derek MuradaliOntario Breast Screening Program, Cancer Care Ontario, Toronto, ON, Canada.
June C CarrollDepartment of Family Medicine, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.
Vicky MajpruzPrevention and Cancer Control, Cancer Care Ontario, Toronto, ON, Canada.
Ellen WarnerMedical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Linda RabeneckPrevention and Cancer Control, Cancer Care Ontario, Toronto, ON, Canada.
Anna M ChiarelliPrevention and Cancer Control, Cancer Care Ontario, Toronto, ON, Canada.ORCID 0000-0002-7382-513X
Cancer Care Ontario · CASunnybrook Health Science Centre · CAUniversity of Toronto · CAMount Sinai Hospital · CANorth York General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Ontario Breast Screening Program (OBSP) expanded in July 2011 to screen high-risk women aged 30-69 with annual MRI and mammography. This study evaluated wait time (WT) indicators along the genetic assessment (GA) pathway for women referred to the High Risk OBSP.

methodsInformation was collected for 27,170 women referred to the High Risk OBSP from July 2011 to June 2015 and followed for GA until June 2016. Median duration (days), interquartile range (IQR) were measured for each WT indicator by program year, age, prior breast cancer, and risk criteria.

resultsAmong 24,811 women who completed GA, 16,367 (66.0%) had genetic counseling only, 8,444 (34.0%) had counseling and testing and 8,027 (32.4%) met the high risk criteria. Median WT from physician visit to first screen was longer for women having genetic counseling only compared to those having counseling and testing (244 vs. 197 days). Women having counseling only also experienced the longest WT from physician visit to genetic counseling (88 days; IQR = 10-174), which increased by year from 71 to 100 days (p < .0001). Among women having counseling and testing, WT from physician visit to counseling was shortest for mutation carriers (39 days; IQR = 4-100). Median WT from testing to laboratory report issue was 41 days (IQR = 22-70) and 17 days to disclosure of test results (IQR = 7-33). Both WTs decreased with year and were shorter for mutation carriers (33 days, IQR = 19-58; 15 days, IQR = 7-28, respectively).

conclusionsAfter implementation of the High Risk OBSP, women received timely genetic counseling, in particular those having counseling and testing. Effective triage models for physicians could reduce WT to GA after physician referral.

Indexed as

Waiting ListsAdultAgedBreastBreast NeoplasmsFemaleGenetic CounselingGenetic Predisposition to DiseaseHumansMagnetic Resonance ImagingMammographyMass ScreeningMiddle AgedOntarioReferral and ConsultationBRCA1BRCA2genetic counselinggenetic predisposition to diseasegenetic testinghigh riskmagnetic resonance imaging (MRI)mammographyorganized breast screening program

Identifiers

PMID29368425
PMCPMC5902387
OpenAlexW2790785207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.